Germline Testing Holds Promise But Demands a Cautious Approach

Maurie Markman, MD
Published: Thursday, Jan 23, 2020
Maurie Markman, MD, editor in chief, is president of Medicine and Science at Cancer Treatment Centers of America and clinical professor of medicine, Drexel University College of Medicine, Seattle Cancer Care Alliance

Maurie Markman, MD

It is difficult to overstate the excitement within the medical and clinical research communities regarding the potential benefits of our rapidly increasing understanding of the role of specific germline variants in health and disease. Much of the past and current focus of such efforts in oncology has been on defining the risk for the development of malignant disease or determining whether an individual patient with cancer might be an appropriate candidate for a specific antineoplastic agent “targeted” to a particular mutation contained within the malignancy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication